AXA/2026/Q1 earnings press release: Difference between revisions
No edit summary |
PlumBot: publish from draft |
||
| Line 11: | Line 11: | ||
| source_url = https://www-axa-com.cdn.prismic.io/www-axa-com/afoMp8BOoF08xomN_AXA_PR_20260505.pdf |
| source_url = https://www-axa-com.cdn.prismic.io/www-axa-com/afoMp8BOoF08xomN_AXA_PR_20260505.pdf |
||
| archive_file = |
| archive_file = |
||
| intro_sentence = This |
| intro_sentence = This article summarizes AXA's Q1 2026 earnings press release, published on 5 May 2026. |
||
}} |
}} |
||
''This |
''This article summarizes AXA's Q1 2026 earnings press release, published on 5 May 2026.'' |
||
== 1Q26 highlights == |
== 1Q26 highlights == |
||
* Gross written premiums & other revenues '''+6%''' |
* Gross written premiums & other revenues '''+6%''' to '''EUR 38.0bn''' vs. 1Q25 <sup>p. 1</sup>. |
||
* Property & Casualty premiums '''+4%''' to '''EUR 21.5bn''' <sup>p. 1</sup> |
** Property & Casualty premiums '''+4%''' to '''EUR 21.5bn''' <sup>p. 1</sup>. |
||
** Retail premiums '''+7%''' (+4% from price effect |
*** Retail premiums '''+7%''' (comprising '''+4%''' from price effect and '''+3%''' from volumes) <sup>p. 1</sup>. |
||
** Commercial premiums '''+3%''' (equal contributions from price effect and volumes) <sup>p. 1</sup> |
*** Commercial premiums '''+3%''' (with equal contributions from price effect and volumes) <sup>p. 1</sup>. |
||
* Life & Health premiums '''+8%''' to '''EUR 16.5bn''' <sup>p. 1</sup> |
** Life & Health premiums '''+8%''' to '''EUR 16.5bn''' <sup>p. 1</sup>. |
||
** Life premiums '''+8%''' <sup>p. 1</sup> |
*** Life premiums '''+8%''' <sup>p. 1</sup>. |
||
** Health premiums '''+8%''' <sup>p. 1</sup> |
*** Health premiums '''+8%''' <sup>p. 1</sup>. |
||
* Life & Health NB CSM '''+4%''' <sup>p. 1</sup> |
* Life & Health NB CSM '''+4%''' <sup>p. 1</sup>. |
||
* Net flows for Life & Health '''EUR +2.7bn''' <sup>p. 1</sup> |
* Net flows for Life & Health were '''EUR +2.7bn''' <sup>p. 1</sup>. |
||
* Solvency II ratio was '''211%''' as of March 31, 2026 <sup>p. 1</sup> |
* Solvency II ratio was '''211%''' as of March 31, 2026, a decrease of '''-4 points''' vs. January 1, 2026, reflecting resilience in a volatile environment <sup>p. 1</sup>. |
||
* Solvency II ratio decreased by '''-4 points''' vs. January 1, 2026 (post-grandfathering period) <sup>p. 1</sup> |
|||
== Outlook 3 == |
== Outlook 3 == |
||
* AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the '''6-8%''' plan target range <sup>p. 1</sup> |
* AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the '''6-8%''' plan target range <sup>p. 1</sup>. |
||
* AXA will present its new strategic plan for 2027-2029 on September 15, 2026 <sup>p. 1</sup> |
* AXA will present its new strategic plan for 2027-2029 on September 15, 2026 <sup>p. 1</sup>. |
||
* > "AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy," |
* > "AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy," — Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup> |
||
* This performance highlights the continued robust expansion of P&C businesses in both Retail and Commercial, with growth balanced between pricing and volumes <sup>p. 1</sup>. |
|||
* > "In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." <sup>p. 1</sup> |
|||
* Life & Health revenues reflect the continuation of strong momentum from the previous year <sup>p. 1</sup>. |
|||
* > "I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA." <sup>p. 1</sup> |
|||
* > "In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." — Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup> |
|||
* > "I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA." — Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup> |
|||
== Press release == |
|||
* The press release was issued on |
* The press release was issued on May 5, 2026, at 5:45pm CET <sup>p. 1</sup>. |
||
* The 1Q26 activity indicators show sustained revenue momentum <sup>p. 1</sup> |
* The 1Q26 activity indicators show sustained revenue momentum <sup>p. 1</sup>. |
||
* All footnotes for this press release are located on page 7 <sup>p. 1</sup>. |
|||
== 1Q26 key highlights == |
== 1Q26 key highlights == |
||
| Line 47: | Line 49: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's gross written premiums and other revenues for 1Q25 and 1Q26. <sup>p. 2</sup> |
||
! style="text-align:left" | EUR bn |
! style="text-align:left" | EUR bn |
||
! style="text-align:right; width:6em" | 1Q25 |
! style="text-align:right; width:6em" | 1Q25 |
||
| Line 82: | Line 84: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ Solvency II ratio for FY25, January 1, 2026, and 1Q26. <sup>p. 2</sup> |
|+ AXA Group's Solvency II ratio for FY25, January 1, 2026, and 1Q26. <sup>p. 2</sup> |
||
! style="text-align:left" | EUR bn |
! style="text-align:left" | EUR bn |
||
! style="text-align:right; width:6em" | FY25 |
! style="text-align:right; width:6em" | FY25 |
||
| Line 99: | Line 101: | ||
== Activity indicators == |
== Activity indicators == |
||
* Total gross written premiums & other revenues '''+6%''' <sup>p. 2</sup> |
* Total gross written premiums & other revenues were '''+6%''' <sup>p. 2</sup>. |
||
** Property & Casualty '''+4%''' <sup>p. 2</sup> |
** Property & Casualty '''+4%''' <sup>p. 2</sup>. |
||
*** Personal lines '''+7%''' |
*** Personal lines '''+7%''' due to higher volumes and favorable price effect <sup>p. 2</sup>. |
||
*** Commercial lines '''+3%''' |
*** Commercial lines '''+3%''' from higher volumes (notably at AXA XL Insurance) and favorable price effect, mainly in the SME & Mid-market business in Europe and France <sup>p. 2</sup>. |
||
*** AXA XL Reinsurance '''-7%''' |
*** AXA XL Reinsurance '''-7%''', reflecting discipline in softening market conditions <sup>p. 2</sup>. |
||
** Life & Health '''+8%''' <sup>p. 2</sup> |
** Life & Health '''+8%''' <sup>p. 2</sup>. |
||
*** Life premiums '''+8%''' |
*** Life premiums '''+8%''', driven by strong sales in Unit-Linked ('''+16%''') and G/A ('''+9%''') across all geographies, and Protection ('''+4%''') from strong sales in Protection with Savings in Hong Kong and Japan <sup>p. 2</sup>. |
||
*** Health premiums '''+8%''' |
*** Health premiums '''+8%''', driven by favorable price effects across all geographies <sup>p. 2</sup>. |
||
* Solvency II ratio was '''211%''' as of March 31, 2026 <sup>p. 2</sup> |
* Solvency II ratio was '''211%''' as of March 31, 2026 <sup>p. 2</sup>. |
||
* On January 1, 2026, the Solvency II ratio was '''215%''' following the end of the grandfathering period <sup>p. 2</sup> |
* On January 1, 2026, the Solvency II ratio was '''215%''' following the end of the grandfathering period, which resulted in a '''-10 points''' decrease vs. December 31, 2025 <sup>p. 2</sup>. |
||
* The Solvency II ratio |
* The Solvency II ratio decreased by '''-4 points''' vs. January 1, 2026, due to: |
||
* |
** A strong operating return ('''+7 points''') <sup>p. 2</sup>. |
||
** |
** Less accrued dividend and annual share buyback for 1Q26 ('''-6 points''') <sup>p. 2</sup>. |
||
** Unfavorable financial market movements ('''-4 points'''), notably from higher inflation expectations and elevated equity and interest rate volatility <sup>p. 2</sup> |
** Unfavorable financial market movements ('''-4 points'''), notably from higher inflation expectations and elevated equity and interest rate volatility <sup>p. 2</sup>. |
||
== Property & Casualty == |
== Property & Casualty == |
||
| Line 118: | Line 120: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ Property & Casualty gross written premiums and revenues |
|+ Property & Casualty gross written premiums and other revenues for 1Q25 and 1Q26. <sup>p. 3</sup> |
||
! style="text-align:left" | EUR bn |
! style="text-align:left" | EUR bn |
||
! style="text-align:right; width:6em" | 1Q25 |
! style="text-align:right; width:6em" | 1Q25 |
||
| Line 151: | Line 153: | ||
</div> |
</div> |
||
* Gross written premiums & other revenues for |
* Gross written premiums & other revenues for Property & Casualty were '''+4%''' to '''EUR 21.5bn''' <sup>p. 3</sup>. |
||
* Personal lines grew by '''7%''' to '''EUR 7.0bn''' |
* Personal lines grew by '''7%''' to '''EUR 7.0bn''' <sup>p. 3</sup>. |
||
** Europe |
** Europe '''+7%''' from favorable price effects (except in UK & Ireland) and higher volumes <sup>p. 3</sup>. |
||
** France |
** France '''+8%''' with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect <sup>p. 3</sup>. |
||
** Asia, Africa & EME LATAM |
** Asia, Africa & EME LATAM '''+7%''', mainly driven by higher average premiums in Türkiye and higher volumes in Mexico <sup>p. 3</sup>. |
||
* Commercial lines grew by '''3%''' to '''EUR 13.2bn''' |
* Commercial lines grew by '''3%''' to '''EUR 13.2bn''' <sup>p. 3</sup>. |
||
** AXA XL Insurance |
** AXA XL Insurance '''+2%''' from growth in Property and Specialty where margins remain attractive, partly offset by lower volumes in Casualty; pricing overall remains stable vs. 1Q25 <sup>p. 3</sup>. |
||
** France |
** France '''+6%''' from both favorable price effect and higher volumes <sup>p. 3</sup>. |
||
** Asia, Africa & EME-LATAM |
** Asia, Africa & EME-LATAM '''+10%''', mainly driven by higher average premiums in Türkiye <sup>p. 3</sup>. |
||
* AXA XL Reinsurance decreased by '''7%''' to '''EUR 1.2bn''', reflecting lower volumes |
* AXA XL Reinsurance decreased by '''7%''' to '''EUR 1.2bn''', reflecting lower volumes consistent with a focus on profitability in a softer market, with pricing down '''-4%''' <sup>p. 3</sup>. |
||
* Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget <sup>p. 3</sup> |
* Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget <sup>p. 3</sup>. |
||
* The annual natural catastrophe budget of |
* The annual natural catastrophe budget of approximately '''4.5 points''' of combined ratio is maintained <sup>p. 3</sup>. |
||
=== 6 ── === |
|||
* 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability, reflecting their contribution to FY25 figures <sup>p. 4</sup>. |
|||
* All year-on-year changes are on a comparable basis vs. the updated 1Q25 figures <sup>p. 4</sup>. |
|||
* Gross written premiums & other revenues for Life & Health were '''+8%''' to '''EUR 16.5bn''' <sup>p. 4</sup>. |
|||
* Life premiums increased by '''8%''' to '''EUR 10.5bn''' <sup>p. 4</sup>. |
|||
** Unit-Linked '''+16%''' from continued positive sales momentum across geographies <sup>p. 4</sup>. |
|||
** G/A Savings '''+9%''', mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland <sup>p. 4</sup>. |
|||
** Protection '''+4%''', primarily from the continued success of Protection with G/A savings in Hong Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland <sup>p. 4</sup>. |
|||
* Health premiums increased by '''8%''' to '''EUR 5.9bn''', driven by favorable price effects across all geographies <sup>p. 4</sup>. |
|||
* PVEP was '''+8%''' to '''EUR 13.8bn''' <sup>p. 4</sup>. |
|||
** Life '''+10%''', reflecting strong sales across geographies in both Savings ('''+14%''') and Protection ('''+6%'''), partly offset by lower Group Life sales in Switzerland <sup>p. 4</sup>. |
|||
** Health '''+4%''', mainly due to higher Group business volumes in France, partly offset by Japan <sup>p. 4</sup>. |
|||
* NB CSM (pre-tax) increased by '''4%''' to '''EUR 0.6bn''', driven by strong Savings and Protection sales across most geographies, partly offset by unfavorable mix, including lower Group Life sales in Switzerland and Health sales in Japan <sup>p. 4</sup>. |
|||
* NBV (post-tax) was '''+1%''' to '''EUR 0.6bn''', as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China <sup>p. 4</sup>. |
|||
* NBV margin decreased by '''0.3 point''' to '''4.4%''' <sup>p. 4</sup>. |
|||
* Net flows were '''EUR +2.7bn''', compared to '''EUR +2.5bn''' in 1Q25 <sup>p. 4</sup>. |
|||
** Protection: '''EUR +1.8bn''', mainly in Hong Kong and Switzerland in Individual Life, and in Japan in Protection with Unit-Linked product <sup>p. 4</sup>. |
|||
** Unit-Linked: '''EUR +0.7bn''', primarily in France <sup>p. 4</sup>. |
|||
** G/A Savings: '''EUR -0.8bn''', reflecting inflows in capital-light G/A savings ('''EUR +0.7bn''') more than offset by outflows in traditional G/A Savings ('''EUR -1.5bn''') <sup>p. 4</sup>. |
|||
** Health: '''EUR +1.0bn''', mostly from Germany, France, and Japan <sup>p. 4</sup>. |
|||
== Life & Health == |
== Life & Health == |
||
| Line 168: | Line 192: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ Life & Health gross written premiums |
|+ Life & Health gross written premiums and other revenues and new business metrics. <sup>p. 4</sup> |
||
! style="text-align:left" | EUR bn |
! style="text-align:left" | EUR bn |
||
! style="text-align:right; width:6em" | 1Q25 |
! style="text-align:right; width:6em" | 1Q25 |
||
! style="text-align:right; width:6em" | 1Q25 Updated* |
! style="text-align:right; width:6em" | 1Q25 Updated* |
||
! style="text-align:right; width:6em" | 1Q26 |
! style="text-align:right; width:6em" | 1Q26 |
||
! style="text-align:right; width:6em" | Change vs. 1Q25 |
! style="text-align:right; width:6em" | Change vs. 1Q25 updated on a comparable basis |
||
|- |
|- |
||
| style="text-align:left" | Gross written premiums and other revenues |
| style="text-align:left" | Gross written premiums and other revenues |
||
| Line 218: | Line 242: | ||
|} |
|} |
||
</div> |
</div> |
||
* 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability <sup>p. 4</sup> |
|||
* Gross written premiums & other revenues for Life & Health were '''+8%''' to '''EUR 16.5bn''' <sup>p. 4</sup> |
|||
* Life premiums increased by '''8%''' to '''EUR 10.5bn''', driven by: <sup>p. 4</sup> |
|||
** Unit-Linked ('''+16%''') from continued positive sales momentum across geographies <sup>p. 4</sup> |
|||
** G/A Savings ('''+9%''') mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland <sup>p. 4</sup> |
|||
** Protection ('''+4%''') primarily from continued success of Protection with G/A savings in Hong-Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland <sup>p. 4</sup> |
|||
* Health premiums increased by '''8%''' to '''EUR 5.9bn''', driven by favorable price effects across all geographies <sup>p. 4</sup> |
|||
* PVEP was '''+8%''' to '''EUR 13.8bn''', driven by: <sup>p. 4</sup> |
|||
** Life ('''+10%''') reflecting strong sales across geographies in both Savings ('''+14%''') and Protection ('''+6%'''), partly offset by lower Group Life sales in Switzerland <sup>p. 4</sup> |
|||
** Health ('''+4%''') mainly due to higher Group business volumes in France, partly offset by Japan <sup>p. 4</sup> |
|||
* NB CSM (pre-tax) increased by '''4%''' to '''EUR 0.6bn''', driven by strong Savings and Protection sales across most geographies, partly offset by unfavorable mix (lower Group Life sales in Switzerland and Health sales in Japan) <sup>p. 4</sup> |
|||
* NBV (post-tax) was '''+1%''' to '''EUR 0.6bn''', as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China <sup>p. 4</sup> |
|||
* NBV margin decreased by '''0.3 points''' to '''4.4%''' <sup>p. 4</sup> |
|||
* Net flows were '''EUR +2.7bn''', compared to '''EUR +2.5bn''' in 1Q25, driven by: <sup>p. 4</sup> |
|||
** Protection ('''EUR +1.8bn''') mainly in Hong Kong and Switzerland (Individual Life), and Japan (Protection with Unit-Linked product) <sup>p. 4</sup> |
|||
** Unit-Linked ('''EUR +0.7bn''') primarily in France <sup>p. 4</sup> |
|||
** G/A Savings ('''EUR -0.8bn''') reflecting inflows in capital-light G/A savings ('''EUR +0.7bn''') more than offset by outflows in traditional G/A Savings ('''EUR -1.5bn''') <sup>p. 4</sup> |
|||
** Health ('''EUR +1.0bn''') mostly from Germany, France and Japan <sup>p. 4</sup> |
|||
== Ratings == |
== Ratings == |
||
| Line 242: | Line 247: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's insurer financial strength and credit ratings from various agencies. <sup>p. 5</sup> |
||
! style="text-align:left" | Agency |
! style="text-align:left" | Agency |
||
! style="text-align:right; width:9em" | Date of last review |
! style="text-align:right; width:9em" | Date of last review |
||
| Line 248: | Line 253: | ||
! style="text-align:right; width:6em" | Insurer financial strength ratings AXA's principal insurance subsidiaries |
! style="text-align:right; width:6em" | Insurer financial strength ratings AXA's principal insurance subsidiaries |
||
! style="text-align:right; width:6em" | Insurer financial strength ratings Outlook |
! style="text-align:right; width:6em" | Insurer financial strength ratings Outlook |
||
! style="text-align:right; width:9em" | AXA's credit ratings Senior debt of the Company |
! style="text-align:right; width:9em" | AXA's credit ratings 12 Senior debt of the Company |
||
! style="text-align:right; width:6em" | AXA's credit ratings Short-term debt of the Company |
! style="text-align:right; width:6em" | AXA's credit ratings 12 Short-term debt of the Company |
||
|- |
|- |
||
| style="text-align:left" | S&P Global Ratings |
| style="text-align:left" | S&P Global Ratings |
||
| Line 294: | Line 299: | ||
== Scope == |
== Scope == |
||
* France includes insurance activities, banking activities, and holding <sup>p. 6</sup> |
* '''France''': includes insurance activities, banking activities, and holding <sup>p. 6</sup>. |
||
* Europe includes Switzerland (insurance), Germany (insurance and holding), Belgium and Luxemburg (insurance and holding), |
* '''Europe''': includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holding), Italy (insurance activities), Prima (insurance activities), AXA Health International (insurance activities), and AXA Life Europe (insurance activities) <sup>p. 6</sup>. |
||
* AXA XL includes insurance and reinsurance activities and holding <sup>p. 6</sup> |
* '''AXA XL''': includes insurance and reinsurance activities and holding <sup>p. 6</sup>. |
||
* Asia, Africa & EME-LATAM |
* '''Asia, Africa & EME-LATAM''': |
||
** Asia: Japan (insurance and holding), Hong Kong (insurance), Thailand P&C, Indonesia L&S ( |
** '''Asia''': Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (excluding bancassurance entity), China P&C, South Korea, and Asia Holdings are fully consolidated <sup>p. 6</sup>. China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S (bancassurance entity) are consolidated under the equity method and contribute only to NBV, PVEP, underlying earnings, and net income <sup>p. 6</sup>. |
||
** Africa: Egypt (insurance and holding), Morocco (insurance and holding), and Nigeria (insurance and holding) |
** '''Africa''': Egypt (insurance activities and holding), Morocco (insurance activities and holding), and Nigeria (insurance activities and holding) are fully consolidated <sup>p. 6</sup>. |
||
** EME-LATAM: Mexico (insurance), Colombia (insurance), Brazil (insurance and holding), and Türkiye (insurance and holding) |
** '''EME-LATAM''': Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) are fully consolidated <sup>p. 6</sup>. Russia (Reso) (insurance activities) is consolidated under the equity method and contributes only to net income <sup>p. 6</sup>. |
||
** AXA Mediterranean Holdings <sup>p. 6</sup> |
** Also includes AXA Mediterranean Holdings <sup>p. 6</sup>. |
||
* Transversal & Other includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA ( |
* '''Transversal & Other''': includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (including the Group's internal reinsurance activity), and other Central Holdings <sup>p. 6</sup>. |
||
* AXA Investment Managers' disposal to BNP Paribas |
* '''AXA Investment Managers''': disposal to BNP Paribas completed on July 1, 2025 <sup>p. 6</sup>. |
||
== Exchange rates == |
== Exchange rates == |
||
| Line 309: | Line 314: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ Exchange rates for major currencies against the Euro for FY25 and 1Q26. <sup>p. 6</sup> |
|+ Exchange rates for major currencies against the Euro for FY25, 1Q25, and 1Q26. <sup>p. 6</sup> |
||
! style="text-align:left" | For 1 Euro |
! style="text-align:left" | For 1 Euro |
||
! style="text-align:right; width:6em" | FY25 |
! style="text-align:right; width:6em" | FY25 |
||
| Line 349: | Line 354: | ||
== Glossary == |
== Glossary == |
||
* Changes in gross written premiums & other revenues, NBV, PVEP, and NBV Margin are on a comparable basis (constant forex, scope, and methodology) unless otherwise indicated <sup>p. 7</sup> |
* Changes in gross written premiums & other revenues, new business value ('NBV'), present value of expected premiums ('PVEP'), and new business value margin ('NBV Margin') are on a comparable basis (constant forex, scope, and methodology), unless otherwise indicated <sup>p. 7</sup>. |
||
* |
* These terms are defined in the glossary section of the press release <sup>p. 7</sup>. |
||
* The Solvency II ratio |
* The Solvency II ratio is estimated using AXA's internal model, calibrated based on an adverse 1/200 years shock <sup>p. 7</sup>. |
||
* |
* It includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on a full-year dividend of '''EUR 2.32 per share''' to be paid in 2026 for FY25 and an annual share buyback of '''EUR 1.25bn''' announced on February 26, 2026 <sup>p. 7</sup>. |
||
* Annual share buybacks exclude anti-dilutive share buybacks related to disposals and in-force management, |
* Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock-based compensation <sup>p. 7</sup>. |
||
* Dividends and share buybacks are proposed by the Board and submitted to shareholders for approval <sup>p. 7</sup> |
* Dividends and share buybacks are proposed by the Board and submitted to shareholders for approval <sup>p. 7</sup>. |
||
* |
* This estimate should not be considered an indication of actual dividend and share buyback amounts for the 2026 financial year <sup>p. 7</sup>. |
||
* For more information on AXA's internal model and Solvency II disclosures, refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on axa.com <sup>p. 7</sup>. |
|||
* Expected underlying earnings per share ('UEPS') growth for 2026 is a forward-looking statement providing one-off guidance for the last year of the current strategic plan <sup>p. 7</sup> |
|||
* The guidance assumes no significant deterioration in current operating, pricing, and market conditions, and is based on a Natural Catastrophe load of approximately '''4.5 points''', defined as normalized natural catastrophe losses expected in a year expressed as a percentage of gross earned premiums <sup>p. 7</sup>. |
|||
* 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance <sup>p. 7</sup> |
|||
* |
* Natural catastrophe charges include natural catastrophe losses regardless of event size <sup>p. 7</sup>. |
||
* Expected underlying earnings per share ('UEPS') growth for 2026 is a forward-looking statement providing one-off guidance for the last year of the Group's current strategic plan <sup>p. 7</sup>. |
|||
* G/A refers to General account <sup>p. 7</sup> |
|||
* 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance <sup>p. 7</sup>. |
|||
* Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, after which they ceased to qualify as capital under Solvency II <sup>p. 7</sup> |
|||
* |
* Price effect is calculated as a percentage of total gross written premiums of the prior year <sup>p. 7</sup>. |
||
* G/A refers to General Account <sup>p. 7</sup>. |
|||
* Combined ratio is a non-GAAP financial measure (Alternative Performance Measure or APM) <sup>p. 7</sup> |
|||
* Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, after which they ceased to qualify as capital under Solvency II <sup>p. 7</sup>. |
|||
* Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities <sup>p. 7</sup> |
|||
* |
* Natural catastrophe charges include natural catastrophe losses regardless of event size <sup>p. 7</sup>. |
||
* |
* Combined ratio is a non-GAAP financial measure, or alternative performance measure ('APM') <sup>p. 7</sup>. |
||
* Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities <sup>p. 7</sup>. |
|||
* AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 <sup>p. 7</sup> |
|||
* |
* Restricted Tier 1 is rated 'A' by Standard & Poor's and 'A3 (hyb)' by Moody's <sup>p. 7</sup>. |
||
* |
* Tier 2 is rated 'A' by Standard & Poor's and 'A (hyb)' by Moody's <sup>p. 7</sup>. |
||
* |
* AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 <sup>p. 7</sup>. |
||
* All comments and changes for activity indicators are on a comparable basis (constant forex, scope, and methodology) <sup>p. 7</sup>. |
|||
* Actuarial and financial assumptions for NBV and PVEP calculation are updated semi-annually at half-year and full-year <sup>p. 7</sup>. |
|||
* Financial figures and information in this press release have not been audited or subject to limited review by AXA's statutory auditors <sup>p. 7</sup>. |
|||
* '''AM''': AM Best |
* '''AM''': AM Best |
||
* '''AMF''': Autorité des Marchés Financiers |
* '''AMF''': Autorité des Marchés Financiers |
||
| Line 381: | Line 389: | ||
* '''GAAP''': Generally Accepted Accounting Principles |
* '''GAAP''': Generally Accepted Accounting Principles |
||
* '''IFRS''': International Financial Reporting Standards |
* '''IFRS''': International Financial Reporting Standards |
||
* '''LATAM''': Latin America |
|||
* '''LFL''': Like-for-Like |
* '''LFL''': Like-for-Like |
||
* '''NB CSM''': New Business Contractual Service Margin |
* '''NB CSM''': New Business Contractual Service Margin |
||
| Line 387: | Line 394: | ||
* '''OTC QX''': Over The Counter QX |
* '''OTC QX''': Over The Counter QX |
||
* '''PVEP''': Present Value of Expected Premiums |
* '''PVEP''': Present Value of Expected Premiums |
||
* '''SFCR''': Solvency and Financial Condition Report |
|||
* '''SME''': Small and Medium-sized Enterprises |
* '''SME''': Small and Medium-sized Enterprises |
||
* '''SRI''': Socially Responsible Investment |
* '''SRI''': Socially Responsible Investment |
||
* '''UEPS''': Underlying Earnings Per Share |
* '''UEPS''': Underlying Earnings Per Share |
||
* '''UK''': United Kingdom |
|||
* '''UN''': United Nations |
* '''UN''': United Nations |
||
* '''UNEP FI''': United Nations Environment Programme's Finance Initiative |
* '''UNEP FI''': United Nations Environment Programme's Finance Initiative |
||
== About the AXA Group == |
== About the AXA Group == |
||
* The AXA Group is a worldwide leader in insurance with '''156,000''' employees serving over '''92 million''' clients in '''52''' countries <sup>p. 8</sup> |
* The AXA Group is a worldwide leader in insurance with '''156,000''' employees serving over '''92 million''' clients in '''52''' countries <sup>p. 8</sup>. |
||
* In 2025, revenues |
* In 2025, revenues were '''EUR 115.5bn''' and underlying earnings were '''EUR 8.4bn''' <sup>p. 8</sup>. |
||
* The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628) <sup>p. 8</sup> |
* The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628 - Bloomberg: CS FP - Reuters: AXAF.PA) <sup>p. 8</sup>. |
||
* AXA's American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY <sup>p. 8</sup> |
* AXA's American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY <sup>p. 8</sup>. |
||
* The AXA Group is included in main international SRI indexes |
* The AXA Group is included in main international SRI indexes, such as Dow Jones Sustainability Index (DJSI) and FTSE4GOOD <sup>p. 8</sup>. |
||
* |
* It is a founding member of the UN Environment Programme's Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment <sup>p. 8</sup>. |
||
* This press release and regulated information are available on the AXA Group website (axa.com) <sup>p. 8</sup> |
* This press release and regulated information are available on the AXA Group website (axa.com) <sup>p. 8</sup>. |
||
* Certain statements in the press release are forward-looking, |
* Certain statements in the press release are forward-looking, identified by words like 'expects', 'anticipates', 'may', 'plan', or conditional verbs like 'would' and 'could' <sup>p. 8</sup>. |
||
* Statements regarding expected underlying earnings per share ('UEPS') growth for 2026 are forward-looking guidance for the last year of the current strategic plan <sup>p. 8</sup>. |
|||
* Forward-looking statements are identified by words like 'expects', 'anticipates', 'may', 'plan', or conditional verbs like 'would' and 'could' <sup>p. 8</sup> |
|||
* These statements are based on Management's current views and intentions and are subject to change <sup>p. 8</sup>. |
|||
* Statements regarding expected underlying earnings per share ('UEPS') growth for 2026 are forward-looking guidance for the last year of the current strategic plan <sup>p. 8</sup> |
|||
* Undue reliance should not be placed on forward-looking statements due to known and unknown risks and uncertainties, many outside AXA's control, which could cause actual results to differ materially <sup>p. 8</sup>. |
|||
* Forward-looking statements are based on Management's current views and intentions and are subject to change, risks, and uncertainties <sup>p. 8</sup> |
|||
* |
* Each forward-looking statement speaks only at the date of the press release <sup>p. 8</sup>. |
||
* Refer to Part 5 'Risk Factors and Risk Management' of AXA's Universal Registration Document for 2025 for a description of factors, risks, and uncertainties that may affect AXA's business and/or results <sup>p. 8</sup>. |
|||
* AXA disclaims any obligation to update or revise forward-looking statements, except as required by law <sup>p. 8</sup> |
|||
* |
* AXA disclaims any obligation to publicly update or revise forward-looking statements, except as required by applicable laws and regulations <sup>p. 8</sup>. |
||
* |
* The press release refers to non-GAAP financial measures, or alternative performance measures ('APMs'), used by Management for analyzing operating trends, financial performance, and position <sup>p. 8</sup>. |
||
* |
* These non-GAAP financial measures generally have no standardized meaning and may not be comparable to similarly labeled measures used by other companies <sup>p. 8</sup>. |
||
* None of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group's consolidated financial statements and related notes prepared in accordance with IFRS <sup>p. 8</sup>. |
|||
* 'Underlying earnings', UEPS, 'underlying return on equity', 'combined ratio', and 'debt gearing' are APMs as defined in ESMA's guidelines and AMF's position statement <sup>p. 8</sup> |
|||
* 'Underlying earnings', UEPS ('underlying earnings per share'), 'underlying return on equity', 'combined ratio', and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015 <sup>p. 8</sup>. |
|||
* Reconciliations of APMs to financial statements are provided in the 2025 Universal Registration Document <sup>p. 8</sup> |
|||
* AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology) in the 2025 Universal Registration Document, on the pages indicated in Section 2.3.3 'Alternative Performance Measures' <sup>p. 8</sup>. |
|||
* Investor Relations contact: +33.1.40.75.48.42, investor.relations@axa.com <sup>p. 8</sup> |
|||
* For further information on non-GAAP financial measures, see the Glossary in the 2025 Universal Registration Document <sup>p. 8</sup>. |
|||
* Individual Shareholder Relations contact: +33.1.40.75.48.43 <sup>p. 8</sup> |
|||
* Media Relations contact: +33.1.40.75.46.74, ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com <sup>p. 8</sup> |
|||
* Corporate Responsibility strategy information is available at axa.com/en/about-us/strategy-commitments <sup>p. 8</sup> |
|||
* SRI ratings information is available at axa.com/en/investor/sri-ratings-ethical-indexes <sup>p. 8</sup> |
|||
* For Investor Relations, contact +33.1.40.75.48.42 or investor.relations@axa.com <sup>p. 8</sup>. |
|||
== Appendix 1: Earnings == |
|||
* For Individual Shareholder Relations, contact +33.1.40.75.48.43 <sup>p. 8</sup>. |
|||
* For Media Relations, contact +33.1.40.75.46.74 or ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com <sup>p. 8</sup>. |
|||
* This section is titled "APPENDIX 1: GROSS WRITTEN PREMIUMS & OTHER REVENUES BY GEOGRAPHY AND BUSINESS LINE" <sup>p. 9</sup>. |
|||
* Corporate Responsibility strategy information is available at axa.com/en/about-us/strategy-commitments <sup>p. 8</sup>. |
|||
* SRI ratings information is available at axa.com/en/investor/sri-ratings-ethical-indexes <sup>p. 8</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's gross written premiums and other revenues by segment. <sup>p. 9</sup> |
||
! style="text-align:left" | EUR m |
! style="text-align:left" | EUR m |
||
! style="text-align:right; width:6em" | 1Q25 |
! style="text-align:right; width:6em" | 1Q25 |
||
! style="text-align:right; width:6em" | 1Q25 Adjusted |
! style="text-align:right; width:6em" | 1Q25 Adjusted |
||
! style="text-align:right; width:6em" | 1Q26 |
! style="text-align:right; width:6em" | 1Q26 |
||
| Line 518: | Line 524: | ||
* Banking revenues were EUR 26m in 1Q26 and EUR 25m in 1Q25 <sup>p. 9</sup>. |
* Banking revenues were EUR 26m in 1Q26 and EUR 25m in 1Q25 <sup>p. 9</sup>. |
||
* Portfolio of lifestyle and income protection (CLP) premiums were reallocated from France to Transversal <sup>p. 9</sup>. |
* Portfolio of lifestyle and income protection (CLP) premiums were reallocated from France to Transversal <sup>p. 9</sup>. |
||
** |
** CLP premiums in 1Q25 were EUR 198m, with EUR 68m in P&C and EUR 130m in Life & Health <sup>p. 9</sup>. |
||
** |
** CLP premiums in 1Q26 were EUR 201m, with EUR 68m in P&C and EUR 132m in Life & Health <sup>p. 9</sup>. |
||
* International protection and health premiums previously reported under AXA France are now reported under AXA Health International, which is part of Europe <sup>p. 9</sup>. |
* International protection and health premiums previously reported under AXA France are now reported under AXA Health International, which is part of Europe <sup>p. 9</sup>. |
||
** |
** These premiums were EUR 319m in 1Q25, with EUR 104m in Life and EUR 215m in Health <sup>p. 9</sup>. |
||
** |
** These premiums were EUR 336m in 1Q26, with EUR 103m in Life and EUR 233m in Health <sup>p. 9</sup>. |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's Property & Casualty gross written premiums by segment and line. <sup>p. 10</sup> |
||
! style="text-align:left" | EUR m |
! style="text-align:left" | EUR m |
||
! style="text-align:right; width:6em" | Commercial lines |
! style="text-align:right; width:6em" | Commercial lines |
||
| Line 539: | Line 545: | ||
! style="text-align:right; width:6em" | AXA XL Reinsurance Change |
! style="text-align:right; width:6em" | AXA XL Reinsurance Change |
||
! style="text-align:right; width:6em" | 1Q26 |
! style="text-align:right; width:6em" | 1Q26 |
||
! style="text-align:right; width:6em" | Change |
! style="text-align:right; width:6em" | Total P&C Change |
||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France |
||
| Line 627: | Line 633: | ||
</div> |
</div> |
||
* Changes are |
* Changes are calculated on a comparable basis, accounting for constant forex, scope, and methodology <sup>p. 10</sup>. |
||
* This section includes "Interest Rates (5Y) For the Discounting of P&C Claims Reserves" <sup>p. 10</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's gross written premiums and other revenues by currency. <sup>p. 10</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | EUR |
||
! style="text-align:right; width:6em" | FY25 |
! style="text-align:right; width:6em" | FY25 |
||
! style="text-align:right; width:6em" | 1Q26 |
! style="text-align:right; width:6em" | 1Q26 |
||
|- |
|||
| style="text-align:left" | EUR |
|||
| style="text-align:right" | 2.6% |
|||
| style="text-align:right" | 2.7% |
|||
|- |
|- |
||
| style="text-align:left" | USD |
| style="text-align:left" | USD |
||
| Line 662: | Line 663: | ||
|} |
|} |
||
</div> |
</div> |
||
</table>GIE_AXA_Internal |
|||
GIE_AXA_Secret GIE_AXA_Internal GIE_AXA_Secret |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ Property & Casualty price effect by country and business line for 1Q26. <sup>p. 11</sup> |
||
! style="text-align:left" | P&C: Price effect by country and business line 1Q26 (in %) |
! style="text-align:left" | P&C: Price effect by country and business line 1Q26 (in %) |
||
! style="text-align:right; width:6em" | Commercial lines |
! style="text-align:right; width:6em" | P&C: Price effect by country and business line Commercial lines |
||
! style="text-align:right; width:6em" | Personal lines |
! style="text-align:right; width:6em" | P&C: Price effect by country and business line Personal lines |
||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France |
||
| Line 701: | Line 699: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ Property & Casualty price effect for Spain and Italy, and AXA XL. <sup>p. 11</sup> |
||
! style="text-align:left" | Spain |
! style="text-align:left" | Spain |
||
! style="text-align:right; width:6em" | +5.7% |
! style="text-align:right; width:6em" | +5.7% |
||
| Line 715: | Line 713: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ Property & Casualty price effect for Asia, Africa & EME-LATAM. <sup>p. 11</sup> |
||
! style="text-align:left" | Asia, Africa & EME-LATAM |
! style="text-align:left" | Asia, Africa & EME-LATAM |
||
! style="text-align:right; width:6em" | +0.4% |
! style="text-align:right; width:6em" | +0.4% |
||
! style="text-align:right; width:6em" | +5.6% |
! style="text-align:right; width:6em" | +5.6% |
||
! style="text-align:right; width:6em" | -3.9% |
|||
|- |
|- |
||
| style="text-align:left" | Total |
| style="text-align:left" | Total |
||
| Line 726: | Line 725: | ||
|} |
|} |
||
</div> |
</div> |
||
* This section is blank <sup>p. 12</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's gross written premiums and other revenues by business line. <sup>p. 12</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Gross written premiums & other revenues |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | Total |
||
! style="text-align:right; width:6em" | Change |
! style="text-align:right; width:6em" | Total Change |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | Protection |
||
! style="text-align:right; width:6em" | Change |
! style="text-align:right; width:6em" | Protection Change |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | G/A Savings |
||
! style="text-align:right; width:6em" | Change |
! style="text-align:right; width:6em" | G/A Savings Change |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | Unit-Linked |
||
! style="text-align:right; width:6em" | Change |
! style="text-align:right; width:6em" | Unit-Linked Change |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | Health |
||
! style="text-align:right; width:6em" | Change |
! style="text-align:right; width:6em" | Health Change |
||
|- |
|||
| style="text-align:left" | in Euro million |
|||
| style="text-align:right" | 1Q26 |
|||
| style="text-align:right" | Change ii |
|||
| style="text-align:right" | 1Q26 |
|||
| style="text-align:right" | Change ii |
|||
| style="text-align:right" | 1Q26 |
|||
| style="text-align:right" | Change ii |
|||
| style="text-align:right" | 1Q26 |
|||
| style="text-align:right" | Change ii |
|||
| style="text-align:right" | 1Q26 |
|||
| style="text-align:right" | Change ii |
|||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France |
||
| Line 834: | Line 843: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's 1Q25 updated figures for gross written premiums and other revenues. <sup>p. 13</sup> |
||
! style="text-align:left" | 1Q25 Updated figures |
! style="text-align:left" | 1Q25 Updated figures |
||
! style="text-align:right; width:6em" | 1Q25 Updated figures |
! style="text-align:right; width:6em" | 1Q25 Updated figures |
||
| Line 844: | Line 853: | ||
! style="text-align:right; width:9em" | 1Q25 Updated figures |
! style="text-align:right; width:9em" | 1Q25 Updated figures |
||
! style="text-align:right; width:9em" | 1Q25 Updated figures |
! style="text-align:right; width:9em" | 1Q25 Updated figures |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | Total |
||
! style="text-align:right; width:9em" | |
! style="text-align:right; width:9em" | Total |
||
! style="text-align:right; width:9em" | |
! style="text-align:right; width:9em" | Total |
||
! style="text-align:right; width:9em" | |
! style="text-align:right; width:9em" | Total |
||
|- |
|- |
||
| style="text-align:left" | — |
| style="text-align:left" | — |
||
| Line 863: | Line 872: | ||
| style="text-align:right" | Total i |
| style="text-align:right" | Total i |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | in Euro million |
||
| style="text-align:right" | PVEP |
| style="text-align:right" | PVEP |
||
| style="text-align:right" | NB CSM (pre-tax) |
| style="text-align:right" | NB CSM (pre-tax) |
||
| Line 951: | Line 960: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's 1H25 updated figures for gross written premiums and other revenues. <sup>p. 13</sup> |
||
! style="text-align:left" | 1H25 Updated figures |
! style="text-align:left" | 1H25 Updated figures |
||
! style="text-align:right; width:6em" | 1H25 Updated figures |
! style="text-align:right; width:6em" | 1H25 Updated figures |
||
! style="text-align:right; width:9em" | 1H25 Updated figures |
! style="text-align:right; width:9em" | 1H25 Updated figures |
||
! style="text-align:right; width:9em" | 1H25 Updated figures |
! style="text-align:right; width:9em" | 1H25 Updated figures |
||
! style="text-align:right; width:9em" | 1H25 Updated figures |
|||
! style="text-align:right; width:6em" | 1H25 Updated figures |
|||
! style="text-align:right; width:9em" | 1H25 Updated figures |
|||
! style="text-align:right; width:9em" | 1H25 Updated figures |
|||
! style="text-align:right; width:9em" | 1H25 Updated figures |
|||
! style="text-align:right; width:6em" | Total |
|||
! style="text-align:right; width:9em" | Total |
|||
! style="text-align:right; width:9em" | Total |
|||
! style="text-align:right; width:9em" | Total |
|||
|- |
|- |
||
| style="text-align:left" | — |
| style="text-align:left" | — |
||
| Line 971: | Line 989: | ||
| style="text-align:right" | Total i |
| style="text-align:right" | Total i |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | in Euro million |
||
| style="text-align:right" | PVEP |
| style="text-align:right" | PVEP |
||
| style="text-align:right" | NB CSM (pre-tax) |
| style="text-align:right" | NB CSM (pre-tax) |
||
| Line 1,059: | Line 1,077: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's 9M25 updated figures for gross written premiums and other revenues. <sup>p. 13</sup> |
||
! style="text-align:left" | 9M25 Updated figures |
! style="text-align:left" | 9M25 Updated figures |
||
! style="text-align:right; width:6em" | 9M25 Updated figures |
! style="text-align:right; width:6em" | 9M25 Updated figures |
||
| Line 1,069: | Line 1,087: | ||
! style="text-align:right; width:9em" | 9M25 Updated figures |
! style="text-align:right; width:9em" | 9M25 Updated figures |
||
! style="text-align:right; width:9em" | 9M25 Updated figures |
! style="text-align:right; width:9em" | 9M25 Updated figures |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | Total |
||
! style="text-align:right; width:9em" | |
! style="text-align:right; width:9em" | Total |
||
! style="text-align:right; width:9em" | |
! style="text-align:right; width:9em" | Total |
||
! style="text-align:right; width:9em" | |
! style="text-align:right; width:9em" | Total |
||
|- |
|- |
||
| style="text-align:left" | — |
| style="text-align:left" | — |
||
| Line 1,088: | Line 1,106: | ||
| style="text-align:right" | Total i |
| style="text-align:right" | Total i |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | in Euro million |
||
| style="text-align:right" | PVEP |
| style="text-align:right" | PVEP |
||
| style="text-align:right" | NB CSM (pre-tax) |
| style="text-align:right" | NB CSM (pre-tax) |
||
| Line 1,173: | Line 1,191: | ||
|} |
|} |
||
</div> |
</div> |
||
</table>Caption: |
</table>Caption: AXA Group's NB CSM to NBV for 1Q25 updated figures. <sup>p. 13</sup> |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's NB CSM to NBV for 1H25 updated figures. <sup>p. 13</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | NB CSM to NBV 1Q25 Updated figures |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | NB CSM to NBV 1Q25 Updated figures |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | NB CSM to NBV 1Q25 Updated figures |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | NB CSM to NBV 1Q25 Updated figures |
||
|- |
|||
| style="text-align:left" | in Euro million |
|||
| style="text-align:right" | Life |
|||
| style="text-align:right" | Health i |
|||
| style="text-align:right" | Total i |
|||
|- |
|- |
||
| style="text-align:left" | NB CSM (pre-tax) |
| style="text-align:left" | NB CSM (pre-tax) |
||
| Line 1,207: | Line 1,230: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's NB CSM to NBV for 9M25 updated figures. <sup>p. 13</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | 1H25 Updated figures NB CSM to NBV |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | 1H25 Updated figures NB CSM to NBV |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | 1H25 Updated figures NB CSM to NBV |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | 1H25 Updated figures NB CSM to NBV |
||
|- |
|||
| style="text-align:left" | in Euro million |
|||
| style="text-align:right" | Life |
|||
| style="text-align:right" | Health i |
|||
| style="text-align:right" | Total i |
|||
|- |
|- |
||
| style="text-align:left" | NB CSM (pre-tax) |
| style="text-align:left" | NB CSM (pre-tax) |
||
| Line 1,237: | Line 1,265: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
! style="text-align:left" | |
! style="text-align:left" | NB CSM to NBV 9M25 Updated figures |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | NB CSM to NBV 9M25 Updated figures |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | NB CSM to NBV 9M25 Updated figures |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | NB CSM to NBV 9M25 Updated figures |
||
|- |
|||
| style="text-align:left" | in Euro million |
|||
| style="text-align:right" | Life |
|||
| style="text-align:right" | Health i |
|||
| style="text-align:right" | Total i |
|||
|- |
|- |
||
| style="text-align:left" | NB CSM (pre-tax) |
| style="text-align:left" | NB CSM (pre-tax) |
||
| Line 1,264: | Line 1,297: | ||
</div> |
</div> |
||
* |
* Changes are compared against 1Q25 updated figures, which are based on FY25 financial and actuarial assumptions <sup>p. 14</sup>. |
||
Caption: Earnings by segment for 1Q26 with various changes. <sup>p. 14</sup> |
|||
| EUR m | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | |
|||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ---|------| |
|||
| France iii,iv | 3,348 | +11% | 96 | +2% | 112 | +8% | 3.3% | -0.1 pt | 1,815 | +16% | — | — | 46 | +5% | 2.5% | -0.3 pt | 5,162 | +12% | 96 | +2% | 158 | +7% | 3.1% | -0.1 pt | | |
|||
| Europe iv | 3,287 | +8% | 187 | -1% | 156 | -5% | 4.8% | -0.7 pt | 1,707 | +4% | 89 | +17% | 77 | +15% | 4.5% | +0.4 pt | 4,994 | +7% | 275 | +4% | 233 | 0% | 4.7% | -0.3 pt | | |
|||
| Asia, Africa & EME-LATAM | 3,129 | +11% | 178 | +13% | 178 | +7% | 5.7% | -0.2 pt | 407 | -26% | 46 | -22% | 37 | -32% | 9.1% | -0.8 pt | 3,536 | +5% | 224 | +4% | 215 | -2% | 6.1% | -0.5 pt | | |
|||
| Transversal iii | 67 | +7% | 5 | +7% | 3 | +7% | 5.2% | 0.0 pt | — | — | — | — | — | — | — | — | 67 | +7% | 5 | +7% | 3 | +7% | 5.2% | 0.0 pt | | |
|||
| Total | 9,831 | +10% | 466 | +5% | 450 | +3% | 4.6% | -0.3 pt | 3,929 | +4% | 135 | -1% | 160 | -4% | 4.1% | -0.4 pt | 13,760 | +8% | 601 | +4% | 609 | +1% | 4.4% | -0.3 pt | | |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's Life and Health new business metrics for 1Q26. <sup>p. 14</sup> |
||
! style="text-align:left" | EUR m |
! style="text-align:left" | EUR m |
||
! style="text-align:right; width:6em" | Life |
! style="text-align:right; width:6em" | Life New Business Metrics 1Q26 PVEP |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | Life New Business Metrics 1Q26 Change |
||
! style="text-align:right; width:6em" | |
! style="text-align:right; width:6em" | Life New Business Metrics 1Q26 NB CSM (pre-tax) |
||
! style="text-align:right; width:6em" | Life New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Life New Business Metrics 1Q26 NBV (post-tax) |
|||
! style="text-align:right; width:6em" | Life New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Life New Business Metrics 1Q26 NBV margin (%) |
|||
! style="text-align:right; width:6em" | Life New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Health New Business Metrics 1Q26 PVEP |
|||
! style="text-align:right; width:6em" | Health New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Health New Business Metrics 1Q26 NB CSM (pre-tax) |
|||
! style="text-align:right; width:6em" | Health New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Health New Business Metrics 1Q26 NBV (post-tax) |
|||
! style="text-align:right; width:6em" | Health New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Health New Business Metrics 1Q26 NBV margin (%) |
|||
! style="text-align:right; width:6em" | Health New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Total New Business Metrics 1Q26 PVEP |
|||
! style="text-align:right; width:6em" | Total New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Total New Business Metrics 1Q26 NB CSM (pre-tax) |
|||
! style="text-align:right; width:6em" | Total New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Total New Business Metrics 1Q26 NBV (post-tax) |
|||
! style="text-align:right; width:6em" | Total New Business Metrics 1Q26 Change |
|||
! style="text-align:right; width:6em" | Total New Business Metrics 1Q26 NBV margin (%) |
|||
! style="text-align:right; width:6em" | Total New Business Metrics 1Q26 Change |
|||
|- |
|||
| style="text-align:left" | France iii,iv |
|||
| style="text-align:right" | 3,348 |
|||
| style="text-align:right" | +11% |
|||
| style="text-align:right" | 96 |
|||
| style="text-align:right" | +2% |
|||
| style="text-align:right" | 112 |
|||
| style="text-align:right" | +8% |
|||
| style="text-align:right" | 3.3% |
|||
| style="text-align:right" | -0.1 pt |
|||
| style="text-align:right" | 1,815 |
|||
| style="text-align:right" | +16% |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 46 |
|||
| style="text-align:right" | +5% |
|||
| style="text-align:right" | 2.5% |
|||
| style="text-align:right" | -0.3 pt |
|||
| style="text-align:right" | 5,162 |
|||
| style="text-align:right" | +12% |
|||
| style="text-align:right" | 96 |
|||
| style="text-align:right" | +2% |
|||
| style="text-align:right" | 158 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 3.1% |
|||
| style="text-align:right" | -0.1 pt |
|||
|- |
|||
| style="text-align:left" | Europe iv |
|||
| style="text-align:right" | 3,287 |
|||
| style="text-align:right" | +8% |
|||
| style="text-align:right" | 187 |
|||
| style="text-align:right" | -1% |
|||
| style="text-align:right" | 156 |
|||
| style="text-align:right" | -5% |
|||
| style="text-align:right" | 4.8% |
|||
| style="text-align:right" | -0.7 pt |
|||
| style="text-align:right" | 1,707 |
|||
| style="text-align:right" | +4% |
|||
| style="text-align:right" | 89 |
|||
| style="text-align:right" | +17% |
|||
| style="text-align:right" | 77 |
|||
| style="text-align:right" | +15% |
|||
| style="text-align:right" | 4.5% |
|||
| style="text-align:right" | +0.4 pt |
|||
| style="text-align:right" | 4,994 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 275 |
|||
| style="text-align:right" | +4% |
|||
| style="text-align:right" | 233 |
|||
| style="text-align:right" | 0% |
|||
| style="text-align:right" | 4.7% |
|||
| style="text-align:right" | -0.3 pt |
|||
|- |
|||
| style="text-align:left" | Asia, Africa & EME-LATAM |
|||
| style="text-align:right" | 3,129 |
|||
| style="text-align:right" | +11% |
|||
| style="text-align:right" | 178 |
|||
| style="text-align:right" | +13% |
|||
| style="text-align:right" | 178 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 5.7% |
|||
| style="text-align:right" | -0.2 pt |
|||
| style="text-align:right" | 407 |
|||
| style="text-align:right" | -26% |
|||
| style="text-align:right" | 46 |
|||
| style="text-align:right" | -22% |
|||
| style="text-align:right" | 37 |
|||
| style="text-align:right" | -32% |
|||
| style="text-align:right" | 9.1% |
|||
| style="text-align:right" | -0.8 pt |
|||
| style="text-align:right" | 3,536 |
|||
| style="text-align:right" | +5% |
|||
| style="text-align:right" | 224 |
|||
| style="text-align:right" | +4% |
|||
| style="text-align:right" | 215 |
|||
| style="text-align:right" | -2% |
|||
| style="text-align:right" | 6.1% |
|||
| style="text-align:right" | -0.5 pt |
|||
|- |
|||
| style="text-align:left" | Transversal iii |
|||
| style="text-align:right" | 67 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 5 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 3 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 5.2% |
|||
| style="text-align:right" | 0.0 pt |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 67 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 5 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 3 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 5.2% |
|||
| style="text-align:right" | 0.0 pt |
|||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 9,831 |
|||
| style="text-align:right" | +10% |
|||
| style="text-align:right" | 466 |
|||
| style="text-align:right" | +5% |
|||
| style="text-align:right" | 450 |
|||
| style="text-align:right" | +3% |
|||
| style="text-align:right" | 4.6% |
|||
| style="text-align:right" | -0.3 pt |
|||
| style="text-align:right" | 3,929 |
|||
| style="text-align:right" | +4% |
|||
| style="text-align:right" | 135 |
|||
| style="text-align:right" | -1% |
|||
| style="text-align:right" | 160 |
|||
| style="text-align:right" | -4% |
|||
| style="text-align:right" | 4.1% |
|||
| style="text-align:right" | -0.4 pt |
|||
| style="text-align:right" | 13,760 |
|||
| style="text-align:right" | +8% |
|||
| style="text-align:right" | 601 |
|||
| style="text-align:right" | +4% |
|||
| style="text-align:right" | 609 |
|||
| style="text-align:right" | +1% |
|||
| style="text-align:right" | 4.4% |
|||
| style="text-align:right" | -0.3 pt |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable" style="width:100%" |
|||
|+ AXA Group's NB CSM to NBV breakdown. <sup>p. 14</sup> |
|||
! style="text-align:left" | NB CSM to NBV |
|||
! style="text-align:right; width:6em" | NB CSM to NBV |
|||
! style="text-align:right; width:6em" | NB CSM to NBV |
|||
! style="text-align:right; width:6em" | NB CSM to NBV |
|||
|- |
|||
| style="text-align:left" | in Euro million |
|||
| style="text-align:right" | Life |
|||
| style="text-align:right" | Health i |
|||
| style="text-align:right" | Total i |
|||
|- |
|- |
||
| style="text-align:left" | NB CSM (pre-tax) |
| style="text-align:left" | NB CSM (pre-tax) |
||
| Line 1,306: | Line 1,495: | ||
</div> |
</div> |
||
* This |
* This includes Health business primarily written in Life entities <sup>p. 14</sup>. |
||
* Changes are calculated on a comparable basis (constant forex, scope, and methodology) <sup>p. 14</sup>. |
|||
* This section is titled "APPENDIX 9: OTHER APPENDIX 7: LIFE & HEALTH -NET FLOWS" <sup>p. 15</sup>. |
|||
=== Net flows by business line === |
=== Net flows by business line === |
||
| Line 1,314: | Line 1,501: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's net flows by business line for 1Q25 and 1Q26. <sup>p. 15</sup> |
||
! style="text-align:left" | EUR bn |
! style="text-align:left" | EUR bn |
||
! style="text-align:right; width:6em" | 1Q25 |
! style="text-align:right; width:6em" | 1Q25 |
||
| Line 1,335: | Line 1,522: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's net flows for capital light and traditional G/A savings. <sup>p. 15</sup> |
||
! style="text-align:left" | o/w capital light |
! style="text-align:left" | o/w capital light |
||
! style="text-align:right; width:6em" | +0.6 |
! style="text-align:right; width:6em" | +0.6 |
||
| Line 1,344: | Line 1,531: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" style="width:100%" |
{| class="wikitable" style="width:100%" |
||
|+ |
|+ AXA Group's total Life & Health net flows for Unit-Linked. <sup>p. 15</sup> |
||
! style="text-align:left" | Unit-Linked |
! style="text-align:left" | Unit-Linked |
||
! style="text-align:right; width:6em" | +0.5 |
! style="text-align:right; width:6em" | +0.5 |
||
| Line 1,358: | Line 1,545: | ||
* Capital light G/A encompasses all products without guarantees, with guarantees only at maturity, or with guarantees equal to or lower than 0% <sup>p. 15</sup>. |
* Capital light G/A encompasses all products without guarantees, with guarantees only at maturity, or with guarantees equal to or lower than 0% <sup>p. 15</sup>. |
||
* Investment contracts with no discretionary participation features ('DPF') are included <sup>p. 15</sup>. |
* Investment contracts with no discretionary participation features ('DPF') are included <sup>p. 15</sup>. |
||
* AXA announced the execution of a share repurchase agreement for |
* AXA announced the execution of a share repurchase agreement for up to EUR 1.25bn on February 27, 2026 <sup>p. 16</sup>. |
||
* Upcoming |
* Upcoming investor events include: |
||
** HY26 Earnings Release on July 31, 2026 <sup>p. 16</sup>. |
** HY26 Earnings Release on July 31, 2026 <sup>p. 16</sup>. |
||
** AXA Investor Day on September 15, 2026 <sup>p. 16</sup>. |
** AXA Investor Day on September 15, 2026 <sup>p. 16</sup>. |
||
Revision as of 18:34, 1 June 2026
| Document info | |
|---|---|
| Organization | AXA |
| Year | 2026 |
| Period | Q1 |
| Period label | 1Q26 |
| Document type | Earnings press release |
| Publication date | 2026-05-05 |
| Market timing | Pre-market |
| Language | English |
| Pages | 16 |
| Source | Original URL |
This article summarizes AXA's Q1 2026 earnings press release, published on 5 May 2026.
1Q26 highlights
- Gross written premiums & other revenues +6% to EUR 38.0bn vs. 1Q25 p. 1.
- Property & Casualty premiums +4% to EUR 21.5bn p. 1.
- Retail premiums +7% (comprising +4% from price effect and +3% from volumes) p. 1.
- Commercial premiums +3% (with equal contributions from price effect and volumes) p. 1.
- Life & Health premiums +8% to EUR 16.5bn p. 1.
- Life premiums +8% p. 1.
- Health premiums +8% p. 1.
- Property & Casualty premiums +4% to EUR 21.5bn p. 1.
- Life & Health NB CSM +4% p. 1.
- Net flows for Life & Health were EUR +2.7bn p. 1.
- Solvency II ratio was 211% as of March 31, 2026, a decrease of -4 points vs. January 1, 2026, reflecting resilience in a volatile environment p. 1.
Outlook 3
- AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the 6-8% plan target range p. 1.
- AXA will present its new strategic plan for 2027-2029 on September 15, 2026 p. 1.
- > "AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy," — Alban de Mailly Nesle, Chief Financial Officer of AXA p. 1
- This performance highlights the continued robust expansion of P&C businesses in both Retail and Commercial, with growth balanced between pricing and volumes p. 1.
- Life & Health revenues reflect the continuation of strong momentum from the previous year p. 1.
- > "In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." — Alban de Mailly Nesle, Chief Financial Officer of AXA p. 1
- > "I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA." — Alban de Mailly Nesle, Chief Financial Officer of AXA p. 1
Press release
- The press release was issued on May 5, 2026, at 5:45pm CET p. 1.
- The 1Q26 activity indicators show sustained revenue momentum p. 1.
- All footnotes for this press release are located on page 7 p. 1.
1Q26 key highlights
| EUR bn | 1Q25 | 1Q26 | Change | Change LFL |
|---|---|---|---|---|
| Gross written premiums and other revenues | 37.0 | 38.0 | +3% | +6% |
| o/w Property & Casualty | 21.0 | 21.5 | +2% | +4% |
| o/w Life & Health | 15.5 | 16.5 | +7% | +8% |
| o/w Asset Management | 0.4 | n.m. | n.m. | n.m. |
| EUR bn | FY25 | January 1, 2026 | 1Q26 | Change vs. January 1, 2026 |
|---|---|---|---|---|
| Solvency II ratio (%) | 224% | 215% | 211% | -4pts |
Activity indicators
- Total gross written premiums & other revenues were +6% p. 2.
- Property & Casualty +4% p. 2.
- Personal lines +7% due to higher volumes and favorable price effect p. 2.
- Commercial lines +3% from higher volumes (notably at AXA XL Insurance) and favorable price effect, mainly in the SME & Mid-market business in Europe and France p. 2.
- AXA XL Reinsurance -7%, reflecting discipline in softening market conditions p. 2.
- Life & Health +8% p. 2.
- Life premiums +8%, driven by strong sales in Unit-Linked (+16%) and G/A (+9%) across all geographies, and Protection (+4%) from strong sales in Protection with Savings in Hong Kong and Japan p. 2.
- Health premiums +8%, driven by favorable price effects across all geographies p. 2.
- Property & Casualty +4% p. 2.
- Solvency II ratio was 211% as of March 31, 2026 p. 2.
- On January 1, 2026, the Solvency II ratio was 215% following the end of the grandfathering period, which resulted in a -10 points decrease vs. December 31, 2025 p. 2.
- The Solvency II ratio decreased by -4 points vs. January 1, 2026, due to:
- A strong operating return (+7 points) p. 2.
- Less accrued dividend and annual share buyback for 1Q26 (-6 points) p. 2.
- Unfavorable financial market movements (-4 points), notably from higher inflation expectations and elevated equity and interest rate volatility p. 2.
Property & Casualty
| EUR bn | 1Q25 | 1Q26 | Change LFL | 1Q26 Price effect (in %) |
|---|---|---|---|---|
| Gross written premiums and other revenues | 21.0 | 21.5 | +4% | +1.9% |
| o/w Commercial lines | 13.2 | 13.2 | +3% | +1.5% |
| o/w Personal lines | 6.4 | 7.0 | +7% | +4.0% |
| o/w AXA XL Reinsurance | 1.4 | 1.2 | -7% | -3.9% |
- Gross written premiums & other revenues for Property & Casualty were +4% to EUR 21.5bn p. 3.
- Personal lines grew by 7% to EUR 7.0bn p. 3.
- Europe +7% from favorable price effects (except in UK & Ireland) and higher volumes p. 3.
- France +8% with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect p. 3.
- Asia, Africa & EME LATAM +7%, mainly driven by higher average premiums in Türkiye and higher volumes in Mexico p. 3.
- Commercial lines grew by 3% to EUR 13.2bn p. 3.
- AXA XL Insurance +2% from growth in Property and Specialty where margins remain attractive, partly offset by lower volumes in Casualty; pricing overall remains stable vs. 1Q25 p. 3.
- France +6% from both favorable price effect and higher volumes p. 3.
- Asia, Africa & EME-LATAM +10%, mainly driven by higher average premiums in Türkiye p. 3.
- AXA XL Reinsurance decreased by 7% to EUR 1.2bn, reflecting lower volumes consistent with a focus on profitability in a softer market, with pricing down -4% p. 3.
- Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget p. 3.
- The annual natural catastrophe budget of approximately 4.5 points of combined ratio is maintained p. 3.
6 ──
- 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability, reflecting their contribution to FY25 figures p. 4.
- All year-on-year changes are on a comparable basis vs. the updated 1Q25 figures p. 4.
- Gross written premiums & other revenues for Life & Health were +8% to EUR 16.5bn p. 4.
- Life premiums increased by 8% to EUR 10.5bn p. 4.
- Unit-Linked +16% from continued positive sales momentum across geographies p. 4.
- G/A Savings +9%, mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland p. 4.
- Protection +4%, primarily from the continued success of Protection with G/A savings in Hong Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland p. 4.
- Health premiums increased by 8% to EUR 5.9bn, driven by favorable price effects across all geographies p. 4.
- PVEP was +8% to EUR 13.8bn p. 4.
- Life +10%, reflecting strong sales across geographies in both Savings (+14%) and Protection (+6%), partly offset by lower Group Life sales in Switzerland p. 4.
- Health +4%, mainly due to higher Group business volumes in France, partly offset by Japan p. 4.
- NB CSM (pre-tax) increased by 4% to EUR 0.6bn, driven by strong Savings and Protection sales across most geographies, partly offset by unfavorable mix, including lower Group Life sales in Switzerland and Health sales in Japan p. 4.
- NBV (post-tax) was +1% to EUR 0.6bn, as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China p. 4.
- NBV margin decreased by 0.3 point to 4.4% p. 4.
- Net flows were EUR +2.7bn, compared to EUR +2.5bn in 1Q25 p. 4.
- Protection: EUR +1.8bn, mainly in Hong Kong and Switzerland in Individual Life, and in Japan in Protection with Unit-Linked product p. 4.
- Unit-Linked: EUR +0.7bn, primarily in France p. 4.
- G/A Savings: EUR -0.8bn, reflecting inflows in capital-light G/A savings (EUR +0.7bn) more than offset by outflows in traditional G/A Savings (EUR -1.5bn) p. 4.
- Health: EUR +1.0bn, mostly from Germany, France, and Japan p. 4.
Life & Health
| EUR bn | 1Q25 | 1Q25 Updated* | 1Q26 | Change vs. 1Q25 updated on a comparable basis |
|---|---|---|---|---|
| Gross written premiums and other revenues | 15.5 | — | 16.5 | +8% |
| o/w Life | 9.8 | — | 10.5 | +8% |
| o/w Health | 5.6 | — | 5.9 | +8% |
| PVEP | 13.7 | 13.0 | 13.8 | +8% |
| NB CSM (pre-tax) | 0.6 | 0.6 | 0.6 | +4% |
| NBV (post-tax) | 0.7 | 0.6 | 0.6 | +1% |
| NBV margin | 4.9% | 4.8% | 4.4% | -0.3pt |
Ratings
| Agency | Date of last review | Insurer financial strength ratings AXA SA | Insurer financial strength ratings AXA's principal insurance subsidiaries | Insurer financial strength ratings Outlook | AXA's credit ratings 12 Senior debt of the Company | AXA's credit ratings 12 Short-term debt of the Company |
|---|---|---|---|---|---|---|
| S&P Global Ratings | March 11, 2026 | AA- | AA | Stable | AA- | A-1+ |
| Moody's Investor Service | October 8, 2025 | Aa2 | Aa2 | Stable | Aa3 | P-1 |
| AM Best | October 9, 2025 | A+ Superior | — | Stable | aa Superior | — |
## Glossary
Capital-light G/A products: encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0%.
Contractual service m argin ('CSM') : a component of the carrying amount of the asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders.
Gross written premiums and other revenues: insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities).
New business contractual service m argin ('NB CSM'): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided.
New business value ('NBV'): the value of newly issued contracts during the current year. It consists of the sum of (i) the NB CSM, (ii) the present value of the future profits of Short-Term Business newly issued contracts during the period, carried by Life entities, considering expected renewals, and (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests.
New business value m argin ('NBV Margin'): the ratio of (i) NBV representing the value of newly issued contracts during the current year to (ii) PVEP.
Present value of expected p remiums ('PVEP'): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share.
Scope
- France: includes insurance activities, banking activities, and holding p. 6.
- Europe: includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holding), Italy (insurance activities), Prima (insurance activities), AXA Health International (insurance activities), and AXA Life Europe (insurance activities) p. 6.
- AXA XL: includes insurance and reinsurance activities and holding p. 6.
- Asia, Africa & EME-LATAM:
- Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (excluding bancassurance entity), China P&C, South Korea, and Asia Holdings are fully consolidated p. 6. China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S (bancassurance entity) are consolidated under the equity method and contribute only to NBV, PVEP, underlying earnings, and net income p. 6.
- Africa: Egypt (insurance activities and holding), Morocco (insurance activities and holding), and Nigeria (insurance activities and holding) are fully consolidated p. 6.
- EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) are fully consolidated p. 6. Russia (Reso) (insurance activities) is consolidated under the equity method and contributes only to net income p. 6.
- Also includes AXA Mediterranean Holdings p. 6.
- Transversal & Other: includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (including the Group's internal reinsurance activity), and other Central Holdings p. 6.
- AXA Investment Managers: disposal to BNP Paribas completed on July 1, 2025 p. 6.
Exchange rates
| For 1 Euro | FY25 | 1Q26 | 1Q25 | 1Q26 |
|---|---|---|---|---|
| USD | 1.17 | 1.15 | 1.05 | 1.17 |
| CHF | 0.93 | 0.93 | 0.95 | 0.92 |
| GBP | 0.87 | 0.87 | 0.84 | 0.87 |
| JPY | 184 | 183 | 160 | 184 |
| HKD | 9.14 | 9.03 | 8.19 | 9.14 |
Glossary
- Changes in gross written premiums & other revenues, new business value ('NBV'), present value of expected premiums ('PVEP'), and new business value margin ('NBV Margin') are on a comparable basis (constant forex, scope, and methodology), unless otherwise indicated p. 7.
- These terms are defined in the glossary section of the press release p. 7.
- The Solvency II ratio is estimated using AXA's internal model, calibrated based on an adverse 1/200 years shock p. 7.
- It includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on a full-year dividend of EUR 2.32 per share to be paid in 2026 for FY25 and an annual share buyback of EUR 1.25bn announced on February 26, 2026 p. 7.
- Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock-based compensation p. 7.
- Dividends and share buybacks are proposed by the Board and submitted to shareholders for approval p. 7.
- This estimate should not be considered an indication of actual dividend and share buyback amounts for the 2026 financial year p. 7.
- For more information on AXA's internal model and Solvency II disclosures, refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on axa.com p. 7.
- The guidance assumes no significant deterioration in current operating, pricing, and market conditions, and is based on a Natural Catastrophe load of approximately 4.5 points, defined as normalized natural catastrophe losses expected in a year expressed as a percentage of gross earned premiums p. 7.
- Natural catastrophe charges include natural catastrophe losses regardless of event size p. 7.
- Expected underlying earnings per share ('UEPS') growth for 2026 is a forward-looking statement providing one-off guidance for the last year of the Group's current strategic plan p. 7.
- 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance p. 7.
- Price effect is calculated as a percentage of total gross written premiums of the prior year p. 7.
- G/A refers to General Account p. 7.
- Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, after which they ceased to qualify as capital under Solvency II p. 7.
- Natural catastrophe charges include natural catastrophe losses regardless of event size p. 7.
- Combined ratio is a non-GAAP financial measure, or alternative performance measure ('APM') p. 7.
- Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities p. 7.
- Restricted Tier 1 is rated 'A' by Standard & Poor's and 'A3 (hyb)' by Moody's p. 7.
- Tier 2 is rated 'A' by Standard & Poor's and 'A (hyb)' by Moody's p. 7.
- AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 p. 7.
- All comments and changes for activity indicators are on a comparable basis (constant forex, scope, and methodology) p. 7.
- Actuarial and financial assumptions for NBV and PVEP calculation are updated semi-annually at half-year and full-year p. 7.
- Financial figures and information in this press release have not been audited or subject to limited review by AXA's statutory auditors p. 7.
- AM: AM Best
- AMF: Autorité des Marchés Financiers
- APM: Alternative Performance Measure
- CLP: Credit and Lifestyle Protection
- CSM: Contractual Service Margin
- DJSI: Dow Jones Sustainability Index
- DPF: Discretionary Participation Features
- EME: Emerging Markets Europe
- ESMA: European Securities and Markets Authority
- GAAP: Generally Accepted Accounting Principles
- IFRS: International Financial Reporting Standards
- LFL: Like-for-Like
- NB CSM: New Business Contractual Service Margin
- NBV: New Business Value
- OTC QX: Over The Counter QX
- PVEP: Present Value of Expected Premiums
- SFCR: Solvency and Financial Condition Report
- SME: Small and Medium-sized Enterprises
- SRI: Socially Responsible Investment
- UEPS: Underlying Earnings Per Share
- UN: United Nations
- UNEP FI: United Nations Environment Programme's Finance Initiative
About the AXA Group
- The AXA Group is a worldwide leader in insurance with 156,000 employees serving over 92 million clients in 52 countries p. 8.
- In 2025, revenues were EUR 115.5bn and underlying earnings were EUR 8.4bn p. 8.
- The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628 - Bloomberg: CS FP - Reuters: AXAF.PA) p. 8.
- AXA's American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY p. 8.
- The AXA Group is included in main international SRI indexes, such as Dow Jones Sustainability Index (DJSI) and FTSE4GOOD p. 8.
- It is a founding member of the UN Environment Programme's Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment p. 8.
- This press release and regulated information are available on the AXA Group website (axa.com) p. 8.
- Certain statements in the press release are forward-looking, identified by words like 'expects', 'anticipates', 'may', 'plan', or conditional verbs like 'would' and 'could' p. 8.
- Statements regarding expected underlying earnings per share ('UEPS') growth for 2026 are forward-looking guidance for the last year of the current strategic plan p. 8.
- These statements are based on Management's current views and intentions and are subject to change p. 8.
- Undue reliance should not be placed on forward-looking statements due to known and unknown risks and uncertainties, many outside AXA's control, which could cause actual results to differ materially p. 8.
- Each forward-looking statement speaks only at the date of the press release p. 8.
- Refer to Part 5 'Risk Factors and Risk Management' of AXA's Universal Registration Document for 2025 for a description of factors, risks, and uncertainties that may affect AXA's business and/or results p. 8.
- AXA disclaims any obligation to publicly update or revise forward-looking statements, except as required by applicable laws and regulations p. 8.
- The press release refers to non-GAAP financial measures, or alternative performance measures ('APMs'), used by Management for analyzing operating trends, financial performance, and position p. 8.
- These non-GAAP financial measures generally have no standardized meaning and may not be comparable to similarly labeled measures used by other companies p. 8.
- None of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group's consolidated financial statements and related notes prepared in accordance with IFRS p. 8.
- 'Underlying earnings', UEPS ('underlying earnings per share'), 'underlying return on equity', 'combined ratio', and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015 p. 8.
- AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology) in the 2025 Universal Registration Document, on the pages indicated in Section 2.3.3 'Alternative Performance Measures' p. 8.
- For further information on non-GAAP financial measures, see the Glossary in the 2025 Universal Registration Document p. 8.
- For Investor Relations, contact +33.1.40.75.48.42 or investor.relations@axa.com p. 8.
- For Individual Shareholder Relations, contact +33.1.40.75.48.43 p. 8.
- For Media Relations, contact +33.1.40.75.46.74 or ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com p. 8.
- Corporate Responsibility strategy information is available at axa.com/en/about-us/strategy-commitments p. 8.
- SRI ratings information is available at axa.com/en/investor/sri-ratings-ethical-indexes p. 8.
| EUR m | 1Q25 | 1Q25 Adjusted | 1Q26 | Change vs. 1Q25 Adjusted | Change LFL | 1Q26 | Change LFL | 1Q26 | Change LFL |
|---|---|---|---|---|---|---|---|---|---|
| France i,ii,iii | 8,440 | 7,923 | 8,393 | +6% | +5% | 3,355 | +6% | 5,012 | +4% |
| Europe iii | 15,289 | 15,608 | 16,905 | +8% | +6% | 9,328 | +4% | 7,577 | +9% |
| AXA XL | 6,984 | 6,984 | 6,488 | -7% | 0% | 6,459 | 0% | 29 | -1% |
| Asia, Africa & EME-LATAM | 5,286 | 5,286 | 5,403 | +2% | +11% | 1,719 | +8% | 3,684 | +13% |
| Transversal ii | 525 | 723 | 764 | +6% | +6% | 601 | +8% | 163 | -2% |
| AXA Investment Managers | 443 | 443 | — | n.m. | n.m. | — | — | — | — |
| Total i | 36,967 | 36,967 | 37,953 | +3% | +6% | 21,462 | +4% | 16,464 | +8% |
- Banking revenues were EUR 26m in 1Q26 and EUR 25m in 1Q25 p. 9.
- Portfolio of lifestyle and income protection (CLP) premiums were reallocated from France to Transversal p. 9.
- CLP premiums in 1Q25 were EUR 198m, with EUR 68m in P&C and EUR 130m in Life & Health p. 9.
- CLP premiums in 1Q26 were EUR 201m, with EUR 68m in P&C and EUR 132m in Life & Health p. 9.
- International protection and health premiums previously reported under AXA France are now reported under AXA Health International, which is part of Europe p. 9.
- These premiums were EUR 319m in 1Q25, with EUR 104m in Life and EUR 215m in Health p. 9.
- These premiums were EUR 336m in 1Q26, with EUR 103m in Life and EUR 233m in Health p. 9.
| EUR m | Commercial lines | Commercial lines Change | Personal lines | Personal lines Change | Personal lines | Personal lines Change | Personal lines | Personal lines Change | AXA XL Reinsurance | AXA XL Reinsurance Change | 1Q26 | Total P&C Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | 2,061 | +6% | 766 | +10% | 528 | +4% | 1,294 | +8% | — | — | 3,355 | +6% |
| Europe | 4,388 | +1% | 3,370 | +10% | 1,570 | +2% | 4,940 | +7% | — | — | 9,328 | +4% |
| AXA XL | 5,215 | +2% | — | — | — | — | — | — | 1,244 | -7% | 6,459 | 0% |
| Asia, Africa & EME-LATAM | 952 | +10% | 577 | +8% | 190 | +2% | 767 | +7% | — | — | 1,719 | +8% |
| Transversal | 601 | +8% | — | — | — | — | — | — | — | — | 601 | +8% |
| Total | 13,217 | +3% | 4,712 | +9% | 2,288 | +2% | 7,001 | +7% | 1,244 | -7% | 21,462 | +4% |
- Changes are calculated on a comparable basis, accounting for constant forex, scope, and methodology p. 10.
| EUR | FY25 | 1Q26 |
|---|---|---|
| USD | 4.2% | 4.0% |
| JPY | 1.0% | 1.6% |
| GBP | 4.3% | 4.2% |
| CHF | 0.2% | 0.2% |
| HKD | 3.2% | 2.8% |
| P&C: Price effect by country and business line 1Q26 (in %) | P&C: Price effect by country and business line Commercial lines | P&C: Price effect by country and business line Personal lines |
|---|---|---|
| France | +3.5% | +2.6% |
| Europe | +3.0% | +4.2% |
| Switzerland | +4.0% | +5.1% |
| Germany | +2.5% | +4.2% |
| Belgium & Luxembourg | +2.2% | +2.4% |
| UK & Ireland | +0.5% | -0.9% |
| Spain | +5.7% | +6.0% | |
|---|---|---|---|
| AXA XL ii | -0.2% | — | -3.9% |
| Asia, Africa & EME-LATAM | +0.4% | +5.6% | -3.9% |
|---|---|---|---|
| Total | +1.5% | +4.0% | -3.9% |
| Gross written premiums & other revenues | Total | Total Change | Protection | Protection Change | G/A Savings | G/A Savings Change | Unit-Linked | Unit-Linked Change | Health | Health Change |
|---|---|---|---|---|---|---|---|---|---|---|
| in Euro million | 1Q26 | Change ii | 1Q26 | Change ii | 1Q26 | Change ii | 1Q26 | Change ii | 1Q26 | Change ii |
| France | 5,012 | +4% | 996 | +3% | 1,325 | +1% | 1,437 | +7% | 1,253 | +4% |
| Europe | 7,577 | +9% | 1,986 | 0% | 1,263 | +16% | 1,044 | +24% | 3,283 | +8% |
| AXA XL | 29 | -1% | 15 | +1% | 14 | -2% | — | — | — | — |
| Asia, Africa & EME-LATAM | 3,684 | +13% | 1,764 | +10% | 319 | +27% | 224 | +35% | 1,377 | +10% |
| Transversal | 163 | -2% | 132 | -1% | — | — | — | — | 31 | -5% |
| Total | 16,464 | +8% | 4,893 | +4% | 2,922 | +9% | 2,705 | +16% | 5,944 | +8% |
| o/w short-term iii | 5,436 | +6% | 1,183 | +1% | — | — | — | — | 4,253 | +7% |
- PVEP, NB CSM, NBV, and NBV margin for 1Q25, 1H25, and 9M25 have been updated based on FY25 actuarial and financial assumptions p. 13.
| 1Q25 Updated figures | 1Q25 Updated figures | 1Q25 Updated figures | 1Q25 Updated figures | 1Q25 Updated figures | 1Q25 Updated figures | 1Q25 Updated figures | 1Q25 Updated figures | 1Q25 Updated figures | Total | Total | Total | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | Total i | Total i | Total i | Total i |
| in Euro million | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) |
| France ii,iii | 3,026 | 94 | 103 | 3.4% | 1,565 | — | 44 | 2.8% | 4,591 | 94 | 147 | 3.2% |
| Europe iii | 2,982 | 183 | 161 | 5.4% | 1,627 | 74 | 66 | 4.0% | 4,609 | 257 | 227 | 4.9% |
| Asia, Africa & EME-LATAM | 3,128 | 178 | 185 | 5.9% | 612 | 67 | 61 | 9.9% | 3,740 | 245 | 246 | 6.6% |
| Transversal ii | 63 | 5 | 3 | 5.2% | — | — | — | — | 63 | 5 | 3 | 5.2% |
| Total | 9,199 | 460 | 452 | 4.9% | 3,805 | 141 | 170 | 4.5% | 13,003 | 601 | 623 | 4.8% |
| 1H25 Updated figures | 1H25 Updated figures | 1H25 Updated figures | 1H25 Updated figures | 1H25 Updated figures | 1H25 Updated figures | 1H25 Updated figures | 1H25 Updated figures | 1H25 Updated figures | Total | Total | Total | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | Total i | Total i | Total i | Total i |
| in Euro million | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) |
| France ii,iii | 6,969 | 204 | 245 | 3.5% | 3,261 | — | 82 | 2.5% | 10,229 | 204 | 327 | 3.2% |
| Europe iii | 5,585 | 328 | 271 | 4.8% | 2,109 | 83 | 76 | 3.6% | 7,694 | 410 | 347 | 4.5% |
| Asia, Africa & EME-LATAM | 6,228 | 389 | 380 | 6.1% | 1,120 | 140 | 120 | 10.7% | 7,347 | 529 | 500 | 6.8% |
| Transversal ii | 153 | 12 | 8 | 5.2% | — | — | — | — | 153 | 12 | 8 | 5.2% |
| Total | 18,934 | 934 | 904 | 4.8% | 6,490 | 223 | 278 | 4.3% | 25,424 | 1,156 | 1,182 | 4.6% |
| 9M25 Updated figures | 9M25 Updated figures | 9M25 Updated figures | 9M25 Updated figures | 9M25 Updated figures | 9M25 Updated figures | 9M25 Updated figures | 9M25 Updated figures | 9M25 Updated figures | Total | Total | Total | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | Life | Life | Life | Life | — | — | — | — | Total i | Total i | Total i | Total i |
| in Euro million | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) |
| France ii,iii | 9,911 | 277 | 344 | 3.5% | 4,788 | — | 116 | 2.4% | 14,698 | 277 | 459 | 3.1% |
| Europe iii | 7,900 | 450 | 365 | 4.6% | 3,215 | 114 | 104 | 3.2% | 11,115 | 564 | 469 | 4.2% |
| Asia, Africa & EME-LATAM | 9,408 | 600 | 592 | 6.3% | 1,502 | 199 | 167 | 11.1% | 10,910 | 799 | 759 | 7.0% |
| Transversal ii | 230 | 18 | 12 | 5.2% | — | — | — | — | 230 | 18 | 12 | 5.2% |
| Total | 27,448 | 1,345 | 1,312 | 4.8% | 9,505 | 313 | 387 | 4.1% | 36,953 | 1,659 | 1,698 | 4.6% |
Caption: AXA Group's NB CSM to NBV for 1Q25 updated figures. p. 13
| NB CSM to NBV 1Q25 Updated figures | NB CSM to NBV 1Q25 Updated figures | NB CSM to NBV 1Q25 Updated figures | NB CSM to NBV 1Q25 Updated figures |
|---|---|---|---|
| in Euro million | Life | Health i | Total i |
| NB CSM (pre-tax) | 460 | 141 | 601 |
| Other NBV(pre-tax) | 133 | 82 | 215 |
| Tax | -141 | -53 | -194 |
| Total NBV | 452 | 170 | 623 |
| 1H25 Updated figures NB CSM to NBV | 1H25 Updated figures NB CSM to NBV | 1H25 Updated figures NB CSM to NBV | 1H25 Updated figures NB CSM to NBV |
|---|---|---|---|
| in Euro million | Life | Health i | Total i |
| NB CSM (pre-tax) | 934 | 223 | 1,156 |
| Other NBV(pre-tax) | 258 | 144 | 402 |
| Tax | -288 | -89 | -377 |
| Total NBV | 904 | 278 | 1,182 |
| NB CSM to NBV 9M25 Updated figures | NB CSM to NBV 9M25 Updated figures | NB CSM to NBV 9M25 Updated figures | NB CSM to NBV 9M25 Updated figures |
|---|---|---|---|
| in Euro million | Life | Health i | Total i |
| NB CSM (pre-tax) | 1,345 | 313 | 1,659 |
| Other NBV(pre-tax) | 384 | 198 | 583 |
| Tax | -418 | -125 | -543 |
| Total NBV | 1,312 | 387 | 1,698 |
- Changes are compared against 1Q25 updated figures, which are based on FY25 financial and actuarial assumptions p. 14.
| EUR m | Life New Business Metrics 1Q26 PVEP | Life New Business Metrics 1Q26 Change | Life New Business Metrics 1Q26 NB CSM (pre-tax) | Life New Business Metrics 1Q26 Change | Life New Business Metrics 1Q26 NBV (post-tax) | Life New Business Metrics 1Q26 Change | Life New Business Metrics 1Q26 NBV margin (%) | Life New Business Metrics 1Q26 Change | Health New Business Metrics 1Q26 PVEP | Health New Business Metrics 1Q26 Change | Health New Business Metrics 1Q26 NB CSM (pre-tax) | Health New Business Metrics 1Q26 Change | Health New Business Metrics 1Q26 NBV (post-tax) | Health New Business Metrics 1Q26 Change | Health New Business Metrics 1Q26 NBV margin (%) | Health New Business Metrics 1Q26 Change | Total New Business Metrics 1Q26 PVEP | Total New Business Metrics 1Q26 Change | Total New Business Metrics 1Q26 NB CSM (pre-tax) | Total New Business Metrics 1Q26 Change | Total New Business Metrics 1Q26 NBV (post-tax) | Total New Business Metrics 1Q26 Change | Total New Business Metrics 1Q26 NBV margin (%) | Total New Business Metrics 1Q26 Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France iii,iv | 3,348 | +11% | 96 | +2% | 112 | +8% | 3.3% | -0.1 pt | 1,815 | +16% | — | — | 46 | +5% | 2.5% | -0.3 pt | 5,162 | +12% | 96 | +2% | 158 | +7% | 3.1% | -0.1 pt |
| Europe iv | 3,287 | +8% | 187 | -1% | 156 | -5% | 4.8% | -0.7 pt | 1,707 | +4% | 89 | +17% | 77 | +15% | 4.5% | +0.4 pt | 4,994 | +7% | 275 | +4% | 233 | 0% | 4.7% | -0.3 pt |
| Asia, Africa & EME-LATAM | 3,129 | +11% | 178 | +13% | 178 | +7% | 5.7% | -0.2 pt | 407 | -26% | 46 | -22% | 37 | -32% | 9.1% | -0.8 pt | 3,536 | +5% | 224 | +4% | 215 | -2% | 6.1% | -0.5 pt |
| Transversal iii | 67 | +7% | 5 | +7% | 3 | +7% | 5.2% | 0.0 pt | — | — | — | — | — | — | — | — | 67 | +7% | 5 | +7% | 3 | +7% | 5.2% | 0.0 pt |
| Total | 9,831 | +10% | 466 | +5% | 450 | +3% | 4.6% | -0.3 pt | 3,929 | +4% | 135 | -1% | 160 | -4% | 4.1% | -0.4 pt | 13,760 | +8% | 601 | +4% | 609 | +1% | 4.4% | -0.3 pt |
| NB CSM to NBV | NB CSM to NBV | NB CSM to NBV | NB CSM to NBV |
|---|---|---|---|
| in Euro million | Life | Health i | Total i |
| NB CSM (pre-tax) | 466 | 135 | 601 |
| Other NBV(pre-tax) | 125 | 73 | 198 |
| Tax | -142 | -48 | -190 |
| NBV | 450 | 160 | 609 |
- This includes Health business primarily written in Life entities p. 14.
Net flows by business line
| EUR bn | 1Q25 | 1Q26 |
|---|---|---|
| Health i | +0.8 | +1.0 |
| Protection | +1.8 | +1.8 |
| G/A Savings | -0.7 | -0.8 |
| o/w capital light | +0.6 | +0.7 |
|---|
| Unit-Linked | +0.5 | +0.7 |
|---|---|---|
| Total Life & Health i net flows | +2.5 | +2.7 |
- Health business written predominantly in Life entities is included p. 15.
- Capital light G/A encompasses all products without guarantees, with guarantees only at maturity, or with guarantees equal to or lower than 0% p. 15.
- Investment contracts with no discretionary participation features ('DPF') are included p. 15.
- AXA announced the execution of a share repurchase agreement for up to EUR 1.25bn on February 27, 2026 p. 16.
- Upcoming investor events include:
- HY26 Earnings Release on July 31, 2026 p. 16.
- AXA Investor Day on September 15, 2026 p. 16.
- AXA Investor roundtable on the strategy for AXA key markets on September 21, 2026 p. 16.
- 9M26 Activity Indicators on October 29, 2026 p. 16.